4th Quarter - Report

MEHLMAN CONSULTING, INC. for BIOGEN IDEC INC.

A later version of this report replaces this one, so LegiList's totals use the current version instead. This page shows this version exactly as filed.

Firm
Client
Income
$50,000
Expenses
—

Versions of this report

Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.

Filing Filed Amount Counted
4th Quarter - Report (this page) Jan 17, 2012 $50,000 Replaced
4th Quarter - Amendment Mar 18, 2013 $50,000 Yes

What was lobbied

4 issue areas, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

Health care reform implementation issues; follow on biologics. Prescription drug user fee reauthorization and FDA reform.

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Medicare/Medicaid MMM

Health reform implementation issues. Independent Payment Advisory Board. Medicare Part D Rebate. Part B Reimbursement. Budget Control Act of 2011 (Became PL 112-25 on August 2, 2011) -- Implementation -- SEE CONTINUATION PAGE H.R. 3630, Temporary Payroll Tax Cut Continuation Act of 2011 H.R. 3765, Temporary Payroll Tax Cut Continuation Act of 2011 (Became PL 112-78 on 12/23/11)

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Bills named: H.R. 3765 (112th), H.R. 3630 (112th)

Trade (domestic/foreign) TRD

Support for strong IP protections for biologics and pharmaceuticals, consistent with US law, to be included in the Trans Pacific Partnership (TPP) trade agreement.

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Taxation/Internal Revenue Code TAX

International tax issues, including repatriation, deferral, check the box, pharmaceutical tax and transfer pricing. Budget Control Act of 2011 (Became PL 112-25 on August 2, 2011) -- Implementation

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.